Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > I Missed This one :-)
View:
Post by langosta on Feb 23, 2022 8:10am

I Missed This one :-)

Laser Hair Rejuvenation

Men- by the age of 35, 2/3 of men begin to experience some sort of hair loss. By the age of 50, 85% of men have significantly thinning hair.

Women- by the age of 40, 40% of women have hair loss.

90% of hair loss is genetic and needs to be treated by laser therapy.

Why TheraLASE TLC-2000 is the among the BEST of the LLLT lasers on the market?

Most laser brands targeting hair rejuvenation is a class 2, or at best a 3R laser, which is a low range of light energy (or red waves), 0-1 mW or 1-5 mW to be exact. At most, penetrating 4 inches deep.

The TLC-2000 has both red light and invisible laser diodes, at 660 nm and 905 nm, and is a class 3B device which means it is in a higher range, this model specifically has 100,000 mW of 660nm diodes and 200,000 of 905nm.

What does this mean for you? Better Results.

Hair Rejuvenation for Hair Loss

This low level laser therapy (LLLT) is FDA approved for hair rejuvenation. The laser penetrates into soft tissue in the scalp and increases nutrient absorption and cellular adenosine triphosphate production (ATP). ATP synthesis dramatically increases the mobilization of calcium ion (Ca2+) and cell signaling cascades that lead to increased protein production, intracellular nutrient acquisition, and cell proliferation. This process ultimately leads to a decrease in DHT-dependent disruption of follicular protein and nutrient loss which results in a healthy scalp, healthy, shiny, thick hair and hair loss prevention as well. Hair loss treatments are approximately 20 to 30 minutes. The hair restoration laser is best described as a warming sensation which is comfortable and pain free. *Please be advised that individual results may vary

 

Treatments

Normally a series of treatments are required for best results, 2 sessions a week continuing treatments for 3, 6 or 12 months depending on the severity of the condition.

Hair Loss Program

3 month - $534.00 + HST (avg. $178 per mon

Comment by toade1313 on Feb 23, 2022 8:34am
Recent statistics show the vast majority of hair loss is due to Theralase shareholders waiting for trial results to be published.
Comment by Legit62 on Feb 23, 2022 8:48am
absolute riot, us longs are an aging population, this week probably lost a few extra strands‍‍‍
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250